AstraZeneca (AZN) said Friday that pooled results from its phase 3 Kalos and Logos trials showed Breztri improved lung function by up to 90mL compared with Symbicort and other dual-combination steroid inhalers.

The analysis of 4,300 patients with uncontrolled asthma demonstrated that the triple-therapy also reduced the rate of severe attacks versus the standard budesonide and formoterol treatment, the company said.

No new safety or tolerability signals were identified in the studies, which tested the medicine against current therapeutic options over a period of 24 to 52 weeks, AstraZeneca said.

The company also said the treatment is already authorized in over 80 countries for chronic obstructive pulmonary disease, while filings for its use in asthma are currently under review in all major regions.